已收录 273512 条政策
 政策提纲
  • 暂无提纲
Milestones toward cochlear gene therapy for patients with hereditary hearing loss
[摘要] A number of genes are reportedly responsible for hereditary hearing loss, which accounts for over 50% of all congenital hearing loss cases. Recent advances in genetic testing have enabled the identification of pathogenic variants in many cases, and systems have been developed to provide personalized treatment based on etiology. Gene therapy is expected to become an unprecedented curative treatment. Several reports have demonstrated the successful use of cochlear gene therapy to restore auditory function in mouse models of genetic deafness; however, many hurdles remain to its clinical application in humans. Herein, we focus on the frequency of deafness genes in patients with congenital and late-onset progressive hearing loss and discuss the following points regarding which genes need to be targeted to efficiently proceed with clinical application: (a) which cells' genes are expressed within the cochlea, (b) whether gene transfer to the targeted cells is possible using vectors such as adeno-associated virus, (c) what phenotype of hearing loss in patients is exhibited, and (d) whether mouse models exist to verify the effectiveness of treatment. Moreover, at the start of clinical application, gene therapy in combination with cochlear implantation may be useful for cases of progressive hearing loss.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 环境科学(综合)
[关键词] adeno-associated virus;cochlear implant;electric-acoustic stimulation;gene therapy;genetic deafness;hereditary hearing loss [时效性] 
   浏览次数:1      统一登录查看全文      激活码登录查看全文